Cetraxal Plus
Commercial- Indications
- Acute otitis externa, Otitis media
SVT Investments developed an AI-powered touchless portable device to detect potential COVID-19 symptoms by analyzing oxygenation levels, heart rate, and temperature without direct contact. The device integrates real-time data analysis with WHO datasets to assess risk within seconds. As of October 2020, prototypes were produced and a strategic partnership was signed for commercialization in Japan starting Q2 2021. There was significant early demand with over 230 customer orders on a waiting list at that time[3].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SVT.